18.86
-0.0499(-0.26%)
Currency In USD
| Previous Close | 18.91 |
| Open | 19.83 |
| Day High | 20.06 |
| Day Low | 18.62 |
| 52-Week High | 24.67 |
| 52-Week Low | 6.53 |
| Volume | 75,198 |
| Average Volume | 167,560 |
| Market Cap | 165.11M |
| PE | -2.78 |
| EPS | -6.79 |
| Moving Average 50 Days | 18.42 |
| Moving Average 200 Days | 13.91 |
| Change | -0.05 |
If you invested $1000 in Seres Therapeutics, Inc. (MCRB) 10 years ago, it would be worth $637.38 as of October 20, 2025 at a share price of $18.86. Whereas If you bought $1000 worth of Seres Therapeutics, Inc. (MCRB) shares 5 years ago, it would be worth $596.84 as of October 20, 2025 at a share price of $18.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
GlobeNewswire Inc.
Sep 23, 2025 11:00 AM GMT
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 27, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York C